Verano: The Cannabis Giant Taxed Into a Loss (VRNOF)
🎙 Listen — Q&A podcast
Watch on YouTube ↗RoboSystems equity research · Cannabis sector · Data: FY2025 10-K (filed Mar 12, 2026) and Q1 FY2026 10-Q (filed Apr 30, 2026), read live from the RoboSystems SEC graph (CIK 0001848416, legacy ticker VRNO). Prices and peer multiples web-verified June 2026. Not investment advice. No price target.
1. The Hook
Verano sold $822 million of cannabis in 2025 at a 50% gross margin, generated $229 million of adjusted EBITDA — and paid the federal government $78 million in cash income taxes on a $166 million pretax loss. Read that again. The company lost money before taxes, and the IRS still collected. On an accrual basis it booked $129 million of current income tax for the year. It has done this every single year of its public life: more than $740 million of current taxes provisioned across 2021–2025, on a business that has never once reported a GAAP profit.
That is not mismanagement. It is Section 280E — a tax statute written for drug traffickers that bars a federally illegal cannabis company from deducting payroll, rent, marketing, or interest. Verano is taxed roughly on gross profit, not net income. The result is the central dissonance of this stock: an enterprise valued at roughly 3.3 times EBITDA — the cheapest of the billion-dollar US operators — that looks like a perpetual money-loser on the income statement, yet throws off real cash and carries a $391 million accrued tax reserve the market mostly ignores. The entire investment question is what happens to that $78 million tax check if the drug it sells stops being Schedule I.
2. Company Snapshot
Verano Holdings (OTC: VRNOF; redomiciled to Nevada in November 2025; Cboe Canada: VRNO) is a vertically integrated multi-state operator running 162 dispensaries across 13 states (77 Zen Leaf nationwide; 85 MÜV in Florida) plus 14 cultivation and production facilities, reaching a roughly 89-million-adult population, and ranking #4 in national wholesale market share. Florida is its single largest market by revenue, at 85 medical dispensaries (the state stays medical-only until at least 2028); Pennsylvania, Illinois, New Jersey, Arizona, and Maryland are its other anchors. This coverage is built on the FY2025 10-K and the Q1 FY2026 10-Q, both now loaded in the SEC graph. In June 2026 Verano completed a 1-for-5 reverse split (~367.7 million shares to ~73.9 million) explicitly to prepare for a prospective US exchange listing — no exchange or ticker named yet.
3. The Financial Story
Start with the top line, because it tells you Verano is past its peak. Revenue ran $737.9M (2021) → $879.4M (2022) → $938.5M (2023, the high-water mark) → $878.6M (2024) → $821.5M (2025, down 6.5%). Q1 FY2026 came in at $208.2M, essentially flat versus the year-ago quarter. The decline is concentrated and explainable: Illinois and New Jersey — two large adult-use markets — are in price compression as new dispensary licenses flood supply, while Florida and Arizona saw seasonal softness. Management's pitch is that store growth in IL and NJ is finally slowing and those markets are "rationalizing." But the most recent quarter hints at a turn worth respecting: Q1 2026 retail revenue of $172 million rose for a second straight sequential quarter — with growth in Pennsylvania, Maryland, Arizona, Nevada, Florida, and West Virginia — leaving the softness now isolated to third-party wholesale, where price competition persists. The takeaway: a mature, share-defending operator whose retail engine is stabilizing while its wholesale channel still bleeds price.
Now the part that matters more than the loss line. Verano's gross margin held at 50% in 2025 ($413.5M gross profit) and 47–48% in Q1 2026 — genuine vertical-integration economics. Strip out the non-cash damage and the business is roughly breakeven-to-profitable at the operating level: 2025 carried $183 million of impairments ($86.6M goodwill plus $96.7M of other intangible and asset write-downs), on top of $328 million the year before — the long tail of boom-era M&A being marked down to reality. Goodwill is now just $161 million, and the accumulated deficit sits at negative $1.06 billion, a monument to the 2021 cycle. Back out impairments and 2025 pretax was modestly positive; the GAAP losses are largely paper. Adjusted EBITDA margin did slip to 24% in Q1 2026 ($49 million) — from 28% for full-year 2025 — on heavier promotional activity and an early hardware purchase, but management guides to margin recovery in the back half and another year of cost-outs after stripping $16 million of SG&A in 2025.
The real cash drains are two: interest and 280E. Verano paid $48 million of cash interest and $78 million of cash taxes in 2025. Against $53 million of operating cash flow and $41 million of capex, that left only $12 million of free cash flow — positive, but razor-thin. This is the 280E vise in one sentence: a 50%-margin, $229M-EBITDA business is reduced to barely-positive free cash flow because a tax code written for cartels takes the first ~$78 million of cash off the top. The "so what" is that Verano's GAAP losses overstate distress while its 280E tax bill understates how good the underlying retail economics actually are.
One more line every cannabis analysis must read: the uncertain-tax reserve. Verano hasn't merely deferred 280E — its filings state it has formally taken the position that 280E doesn't limit its deductions at all, deducting ordinary business expenses and reserving the disputed tax. The tax note shows how fast that bet scaled: the reserve was just $3 million at the start of 2024, jumped to $271 million by year-end 2024, hit $378 million at year-end 2025, and reached $391 million by March 31, 2026 — the entire ~$390 million liability built in barely two years. And it isn't static: Verano booked $37 million of interest and penalties into income-tax expense in 2025 alone (after $32 million in 2024), so the reserve compounds even if it adds no new positions. This is a disputed back-tax liability the IRS is actively trying to collect across the industry — hold the number; it's the counterweight to every bull-case scenario below.
4. Catalyst Scenarios — How the Math Changes
280E relief — the whole thesis in one number. On April 28, 2026, FDA-approved and state-licensed medical marijuana moved to Schedule III; adult-use stays Schedule I, and a broader DEA hearing covering recreational marijuana opens June 29, 2026 (under a pending D.C. Circuit stay). Here's why that matters more for Verano than the generic "adult-use-heavy MSO" label implies: on the Q1 call, management disclosed that nearly 60% of retail revenue came from medical cannabis — Florida, Pennsylvania, West Virginia, and the medical side of dual-use states — so a large share of the book qualifies for 280E relief now, in the 2026 tax year, not someday (the IRS has signaled the medical relief covers the full tax year of the order's effective date). The remaining adult-use revenue keeps paying full freight until a broad order lands. The whole prize: if a broad Schedule III order eventually covers adult-use too, Verano's ~$78 million annual cash tax bill largely disappears, and free cash flow steps from ~$12 million to roughly $75–90 million — a six-to-seven-fold increase — with no change to the business itself. On an enterprise value near $800 million, that converts a ~1.5% free-cash-flow yield into roughly 10%. The catalyst doesn't make Verano grow; it lets Verano keep the cash it already earns — and with a majority-medical retail book, a meaningful slice of that benefit should land in 2026, not in some distant future.
The back-tax caveat — relief is not a refund. Crucially, the prospective fix improves future earnings but does not erase the $391 million already reserved. The IRS is fighting retroactive "gambit" refund claims hard — it sued TerrAscend in May 2026 to claw back an $8.3 million refund, the first such action — and aggregate industry back-280E exposure is reportedly ~$1.6 billion. Verano's $391 million is a balance-sheet liability that survives even the bull case, and if the D.C. Circuit stays the partial order, operators that stopped accruing could have to reverse course — a cash-tax whipsaw. On the encouraging side, the IRS has signaled the medical relief applies to the entire 2026 tax year for state medical licensees, not just from the April effective date — but Verano told investors it "is unable to reasonably estimate the effect at this time," and explicitly flagged that the resolution of its accrued uncertain tax positions remains uncertain. Even management won't yet say whether that ~$390 million reserve gets released, settled, or paid. But it isn't passive: on the Q1 call it said it is actively pursuing retroactive refunds on two theories — years it held state medical licenses, or all the way back to the 2023 HHS rescheduling recommendation — and is "pretty confident there will be some action," noting the Attorney General recommended retrospective medical relief. So the reserve is really a two-way option: a liability if the IRS prevails, a potential refund catalyst if Verano does.
Uplisting and consolidation. Verano has done the visible prep: redomiciled to Nevada, executed the 1-for-5 split, and refinanced its debt. But the proven 2026 path onto a major exchange (Trulieve's playbook) is to deconsolidate adult-use into a medical-only entity — and Verano has not announced such a structure or a ticker. Its uplisting readiness is real but unproven. On consolidation, Verano is acting as a buyer of distress, not a target: in 2026 it acquired The Cannabist Company's Arizona operations and a Virginia license out of that company's bankruptcy — picking up assets cheaply while weaker operators are handed to creditors. At ~0.9x revenue and ~3.3x EBITDA, Verano itself is also cheap enough to be an attractive target for a larger MSO or an outside CPG entrant if rescheduling de-risks the sector. On the call, management framed its uplisting path around obtaining a DEA registration (a roughly six-month review) that would make Verano "a federally legal business" — the bar the exchanges actually care about — while staying noncommittal on whether it would adopt Trulieve's medical-only deconsolidation now or wait for broad rescheduling. It also pointed to four forward growth markets — Florida (5–10 new stores in 2026), Pennsylvania (18 dispensaries, adult-use bill pending), Virginia (six stores, adult-use in dialogue), and Texas (medical expansion, hoped-for 2027 launch) — and guided to stronger operating cash flow in 2026, weighted to the back half, as 2025's elevated tax-payable and inventory builds don't recur.
5. Valuation — What It's Worth If It's a Normal Business
Today the market values Verano at roughly a $410–430 million market cap and a ~$800 million enterprise value — about 3.3 times its $229 million of adjusted EBITDA and under 1 times revenue, the lowest multiples of any billion-dollar US operator, at roughly 0.6x book. The market is pricing Verano as a structurally impaired, perpetually-taxed, slowly-shrinking business. The catalyst math says: maybe.
Cross-sector re-rating lens. Consumer-staples and health-and-wellness peers — the businesses Verano would resemble without 280E and federal illegality — trade around 8–14x EBITDA; tobacco names like Altria sit around 8–9x. Apply normalized multiples to Verano's existing $229M EBITDA (which doesn't change when 280E lifts — EBITDA is pre-tax; what changes is how much cash survives to equity) and net out ~$335 million of net debt: at 5x the equity is roughly $810 million (~1.9x today); at 8x, roughly $1.5 billion (~3.5x today); a full CPG-style 10x implies close to $2 billion. The point is not a target — it's that even a partial re-rating toward normal-industry multiples, still well below CPG peers, implies a materially higher equity value than today's price.
Scenario DCF lens. The driver is the free-cash-flow step-change, not growth. In a base case (280E persists, revenue flat-to-down low-single-digits, an elevated ~13–15% WACC appropriate for a Schedule-I OTC name, ~2% terminal growth), discounted free cash flow lands near today's enterprise value — the market is roughly fair on the status quo. In a rescheduling case (broad 280E relief from ~2027, free cash flow stepping to ~$80 million and growing modestly), the same model produces an enterprise value well above today's. The honest output is a band: today's ~$800M EV is defensible if nothing changes, and implied value runs meaningfully higher under stated rescheduling assumptions — call it roughly 1.5x–3x today's equity across the partial-to-full catalyst range. Framed as implied value under stated assumptions, not a forecast and not advice.
6. Risks and Open Questions
The bear case is concrete. The $391 million 280E back-tax reserve is real, owed, accruing daily interest, and largely outside the relief window — and the IRS is litigating to keep it. The April partial order faces a D.C. Circuit stay, and the June 29 DEA hearing was stacked with rescheduling opponents; if the predicate is vacated, the medical relief evaporates and accrual reversals bite. Operationally, revenue has fallen three straight years from the 2023 peak, and Verano's two largest adult-use markets — Illinois and New Jersey — remain in price compression; its biggest footprint, Florida, is locked medical-only until 2028 after the state's adult-use measure failed. The balance sheet carries ~$395 million of debt (nearly $500 million including leases) against $74 million of cash and 1.4x interest coverage — refinanced out to 2029–2030, but leaving little room for error. And the uplisting it is preparing for is not yet structured or confirmed. Two items cut the other way and belong in the ledger: Verano settled the long-running Goodness Growth / Vireo lawsuit — which had sought $861 million in damages over Verano's terminated 2022 acquisition of what is now Vireo — in October 2025 for roughly $10 million, mostly a non-cash transfer of a defunct, non-operational cultivation facility, clearing a large tail liability; and the filings carry no going-concern qualification, with current liabilities cut from $412 million (2023) to $198 million (2024) as debt was termed out. The board even authorized a $20 million share buyback in April 2026 — modest given thin free cash flow, but a vote of confidence in a stock it views as cheap. The open question for every quarter of this coverage: does the effective tax burden actually fall as the medical slice captures relief, or does litigation freeze the whole thing in place — while that reserve compounds at roughly $37 million a year in interest and penalties?
7. The Bottom Line
Verano is the cheapest major US cannabis operator, and it's cheap for understandable reasons: shrinking revenue, perennial GAAP losses, a heavy adult-use mix that waits longest for tax relief, and a $391 million disputed tax overhang. But underneath the losses is a 50%-margin, $229M-EBITDA retail machine whose free cash flow is suppressed almost entirely by a single tax statute. If 280E falls away — partially now on the medical book, potentially in full if adult-use is rescheduled — the same business converts a thin $12 million of free cash flow into $75–90 million, and a 3.3x-EBITDA stock starts to look mispriced against any normal-industry multiple. If rescheduling stalls or the back-taxes come due, it stays a low-multiple, low-growth survivor. That's the framework: a high-operating-leverage bet on the tax code, priced for the status quo. Watch the quarterly current-tax line, the uncertain-tax reserve, and whether Verano announces a medical-only uplisting structure. We'll be tracking all three.
Built with RoboSystems — open-source, structured access to every public company's SEC filings, queried live for this report. Set up the same tools in about five minutes at robosystems.ai. New customers get 50% off your first month with code CANNABIS50.